One capsule per day, consistently
The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
Foresta C, Garolla A, Zuccarello D, Pizzol D, Moretti A, Barzon L, Palu G (2010) Human papillomavirus found in sperm head of young adult males affects the progressive motility
Piel FB, Steinberg MH, Rees DC